You have a condition called thrombocytosis (or thrombocythemia), which means “too many platelets.” This once was considered a condition of older people. It can, in fact, happen at any age.

Assuming the thrombocytosis represents a rebound phenomenon, and is not a manifestation of essential thrombocythemia, in all likelihood, the patient will remain asymptomatic. It is extraordinarily ...

Dear Reader: Essential thrombocytosis is also known as essential or primary thrombocythemia and has no known cause. It occurs when the bone marrow makes too many platelets, which are needed to ...

Aaron T. Gerds, MD, discusses the unmet needs in the treatment of essential thrombocythemia, as well as novel methods for approaching disease treatment.

To the Editor: The treatment of symptomatic thrombocythemia is an unresolved problem of hematology and demands rapid action. Both alkylating agents and radioactive phosphorus require days to act ...

Essential thrombocythemia — a myeloproliferative neoplasm characterized by thrombocytosis —carries a risk for thrombotic and hemorrhagic events. Between 11% and 29% of patients with essential ...

A: Essential thrombocytosis is known as essential or primary thrombocythemia and has no known cause. It occurs when the bone marrow makes too many platelets, which are needed to stop bleeding.

We report phase II trial results of the use of oral anagrelide hydrochloride for treating 38 patients with hydroxyurea (HU)-resistant thrombocytosis accompanying chronic myeloid leukemia (CML).

“It also may improve the burden of [essential thrombocythemia]-related symptoms, especially fatigue, that patients with [essential thrombocythemia] can experience,” he added. “And importantly, it does ...

Dear Reader: Essential thrombocytosis is also known as essential or primary thrombocythemia and has no known cause. It occurs when the bone marrow makes too many platelets, which are needed to ...